Skip to main content

Advertisement

Table 4 Clearance of HPV by male circumcision status

From: Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study

HPV Type Uncircumcised men Circumcised men Log-rank test p HR (95% CI) [circumcised versus uncircumcised]
New infections/Cleared infections Median time to clearance (months; 95% CI) New infections/Cleared infections Median time to clearance (months; 95% CI)
Any HPV a 2973/2392 6.6 (6.4, 6.8) 1841/1480 7.1 (6.8, 7.3) <0.001 0.85 (0.80-0.91)
Oncogenic b 1129/937 6.5 (6.3, 6.8) 767/629 6.7 (6.4, 7.1) <0.001 0.83 (0.75-0.92)
16 145/118 7.1 (6.3, 8.9) 113/79 11.1 (7.2, 18.4) <0.001 0.56 (0.42-0.75)
18 71/63 6.5 (6.1, 8.1) 51/44 6.3 (6.2, 7.2) 0.84 1.04 (0.71-1.54)
31 49/39 7.2 (6.5, 14.5) 37/31 6.4 (6.1, 6.9) 0.23 1.34 (0.83-2.17)
33 16/13 6.9 (5.9, 17.6) 16/16 6 (5.8, 6.6) 0.02 2.54 (1.12-5.73)
35 34/26 11.3 (6.5, 18.1) 18/15 10.8 (7.1, N.E.) 0.86 0.95 (0.50-1.80)
39 83/66 7 (6.3, 17.3) 71/56 11.2 (7.4, 12.8) 0.68 0.93 (0.65-1.32)
45 77/65 6.3 (6.1, 10.6) 51/48 6.1 (6.1, 6.5) 0.23 1.26 (0.87-1.84)
51 144/116 6.4 (6, 7.8) 117/88 8 (6.4, 13.1) 0.02 0.72 (0.54-0.95)
52 139/119 6.4 (6, 7.6) 84/70 6.7 (6.4, 12) 0.20 0.82 (0.61-1.11)
56 58/45 6 (6, 8.9) 44/41 6.3 (6, 7.9) 0.36 1.21 (0.79-1.86)
58 72/59 6.9 (6, 11.4) 34/26 7.1 (6.2, 12.9) 0.20 0.73 (0.46-1.17)
59 122/103 6.2 (6, 6.7) 89/73 6.4 (6.2, 8.5) 0.11 0.78 (0.58-1.06)
68 119/105 6.2 (6, 6.8) 42/42 6.4 (6.2, 10.4) 0.91 0.97 (0.68-1.39)
Non-oncogenic c 1844/1455 6.7 (6.4, 6.9) 1074/851 7.2 (6.9, 7.8) <0.001 0.86 (0.79-0.93)
6 156/142 6.1 (6, 6.4) 80/61 7.8 (6.5, 12.5) <0.001 0.60 (0.44-0.81)
11 37/27 7.8 (6.2, 14) 19/15 6.6 (6, 18.1) 0.54 1.22 (0.65-2.31)
26 17/14 6 (5.9, 7.1) 5/5 6.1 (6, N.E.) 0.62 0.76 (0.27-2.13)
40 47/41 6.4 (6, 7.8) 34/27 6.5 (6.2, 17.6) 0.09 0.66 (0.40-1.08)
42 63/53 9.1 (6.4, 12.3) 21/18 7.8 (6.2, N.E.) 0.96 1.02 (0.59-1.75)
53 150/123 6.7 (6.3, 7.8) 88/68 7.5 (6.2, 12.5) 0.10 0.78 (0.58-1.05)
54 111/86 8.3 (6.4, 12.1) 70/56 6.9 (6.4, 13.1) 0.93 1.02 (0.72-1.42)
55 67/53 7.2 (6.2, 12) 50/37 7 (6.6, 18.2) 0.20 0.76 (0.50-1.16)
61 126/89 6.5 (6.1, 8.5) 48/43 6.9 (6.4, 13.3) 0.86 0.97 (0.67-1.40)
62 148/104 7.9 (6.5, 11.8) 94/73 7.9 (6.7, 12.3) 0.88 1.02 (0.76-1.38)
64 8/8 6 (5.9, N.E.) 2/2 5.7 (5.5, N.E.) 0.04 6.06 (0.84-43.74)
66 110/90 6.8 (6.2, 8.5) 87/69 7.1 (6.5, 11.9) 0.49 0.89 (0.65-1.23)
67 35/32 6 (6, 7.2) 19/19 6.3 (6, 7.4) 0.38 1.28 (0.71-2.31)
69 9/9 6 (5.7, N.E.) 2/2 7.1 (6.2, N.E.) 0.99 0.98 (0.20-4.93)
70 62/53 6.8 (6.2, 11.7) 32/28 6.7 (6.2, 12) 0.54 1.15 (0.73-1.83)
71 54/39 7.5 (6.2, 13) 14/9 7.5 (6, N.E.) 0.53 0.79 (0.38-1.64)
72 49/43 6.1 (6, 7.4) 25/23 6.2 (6, 7.1) 0.35 1.28 (0.76-2.17)
73 49/39 6.2 (6, 9.2) 35/30 7.6 (6.6, 13.6) 0.45 0.83 (0.51-1.33)
81 94/72 7.2 (6.4, 10.3) 39/35 6.6 (6.2, 11.5) 0.29 1.25 (0.83-1.88)
82 30/26 6.2 (6, 11.7) 25/21 6.4 (6.2, 14.2) 0.28 0.73 (0.40-1.32)
83 55/45 6.9 (6, 9.5) 32/25 8 (6.4, 13.9) 0.25 0.75 (0.46-1.22)
84 170/126 7.2 (6.4, 11.4) 131/91 10.4 (6.7, 13.8) 0.07 0.78 (0.60-1.03)
89 166/116 7.2 (6.3, 11.5) 115/88 8.4 (7.7, 12.5) 0.15 0.81 (0.62-1.07)
IS39 31/25 6.2 (6, 13.2) 7/6 13.1 (5.9, N.E.) 0.78 0.87 (0.35-2.12)
  1. aAny HPV was defined as at least one of 37 HPV genotypes;
  2. bOncogenic HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68;
  3. cNon-oncogenic HPV types: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89 (CP6108), and IS39;
  4. NOTE: Analysis of clearance was limited to incident HPV detection; NE, not estimable; HR, hazard ratio; CI, confidence interval.